SCHEMBL23945202

SCHEMBL23945202

CC(C)OCC(=O)NCCCCCNC=O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ ADH1B P00325 2/20 0.41
▸ ADH1C P00326 2/20 0.41
▸ ADH1A P07327 2/20 0.41
▸ ADH7 P40394 2/20 0.41
▸ EPHX1 P07099 1/20 0.41
▸ ADH4 P08319 1/20 0.41
▸ LMNA P02545 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ MEN1 O00255 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ CASP2 P42575 1/20 0.37
▸ POLB P06746 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25466978 1.00 FAAH (0.42) FAAHALDH1A1ADH1BADH1CADH1A
SCHEMBL25591306 0.98 ALDH1A1 (0.42) FAAHALDH1A1ADH1BADH1CADH1A
SCHEMBL24607224 0.93 EPHX2 (0.43) FAAHALDH1A1ADH1BADH1CADH1A
SCHEMBL24608172 0.91 EPHX2 (0.44) FAAHALDH1A1ADH1BADH1CADH1A
SCHEMBL24935617 0.90 ALDH1A1 (0.36) FAAHALDH1A1ADH1BADH1CADH1A
SCHEMBL25090249 0.86 ALDH1A1 (0.51) FAAHALDH1A1LMNAKMT2ASMN1; SMN2
SCHEMBL23945678 0.84 KMT2A (0.41) FAAHALDH1A1ADH1BADH1AADH7
SCHEMBL25123095 0.83 FAAH (0.45) FAAHALDH1A1EPHX1LMNAKMT2A
SCHEMBL22861669 0.83 KMT2A (0.61) FAAHALDH1A1EPHX1LMNAKMT2A
SCHEMBL21107467 0.83 KDM4E (0.57) FAAHALDH1A1LMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 FAAH 1771/4885ALDH1A1 2776/4885ADH1B 3094/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 FAAH 1771/4885ALDH1A1 2776/4885ADH1B 3094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback